Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639953 | 1.00 | PNMT (0.41) | PNMTCYP3A4POLBSMN1; SMN2HTR2C | |
| Hydrochloric Acid SCHEMBL6608089 | 0.98 | PNMT (0.40) | PNMTCYP3A4POLBSMN1; SMN2HTR2C | |
| SCHEMBL20330372 | 0.85 | HTR2C (0.41) | PNMTHTR2CHTR2BDRD2DRD1 | |
| SCHEMBL8260982 | 0.82 | DRD2 (0.35) | DRD2DRD1 | |
| SCHEMBL722943 | 0.78 | PNMT (0.50) | PNMTCYP3A4POLBSMN1; SMN2HTR2C | |
| SCHEMBL14637150 | 0.78 | HTR2C (0.40) | PNMTCYP3A4POLBSMN1; SMN2HTR2C | |
| SCHEMBL13226202 | 0.78 | MB (0.40) | PNMTCYP3A4POLBSMN1; SMN2HTR2C | |
| SCHEMBL694665 | 0.78 | PNMT (0.50) | PNMTCYP3A4POLBSMN1; SMN2HTR2C | |
| SCHEMBL5457714 | 0.78 | CYP3A4 (0.40) | PNMTCYP3A4POLBSMN1; SMN2HTR2C | |
| SCHEMBL29883454 | 0.78 | PNMT (0.50) | PNMTCYP3A4POLBSMN1; SMN2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0997462-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | claimed |
| US-20250002507-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-01-02 | — | — | US | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023064587-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064584-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1453836-B1 | BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| US-6916811-B2 | Adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| EP-0997462-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | NIPPON KAYAKU KK (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1448565-A1 | ADENOSINE A?2a? RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030212059-A1 | Adenosine A2a receptor antagonists | SCHERING CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2003048165-A1 | ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048165-A1 | ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6294547-B1 | Naphthyridine deratives or salts thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-09-25 | — | — | US | disclosed |
| EP-0997462-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | PNMT 1328/4885CYP3A4 2981/4885POLB 2793/4885 |
| US-20250002507-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM4, CHRM1, CHRM2 | PNMT 523/4885CYP3A4 1019/4885POLB 3224/4885 |
| US-20030212059-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | PNMT 1046/4885CYP3A4 1103/4885POLB 3866/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | PNMT 3139/4885CYP3A4 3434/4885POLB 3294/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | PNMT 3139/4885CYP3A4 3434/4885POLB 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.